Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 16,582 shares of Evolus stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the sale, the insider now owns 364,927 shares of the company's stock, valued at $3,609,128.03. This represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
David Moatazedi also recently made the following trade(s):
- On Friday, June 13th, David Moatazedi sold 111,323 shares of Evolus stock. The stock was sold at an average price of $10.05, for a total transaction of $1,118,796.15.
- On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The shares were sold at an average price of $9.87, for a total transaction of $155,817.69.
- On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The shares were sold at an average price of $12.40, for a total value of $77,512.40.
Evolus Stock Performance
Shares of NASDAQ:EOLS traded up $0.03 during midday trading on Monday, hitting $9.96. The company had a trading volume of 762,050 shares, compared to its average volume of 742,318. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The company has a fifty day moving average of $10.31 and a two-hundred day moving average of $11.77. The company has a market cap of $642.18 million, a price-to-earnings ratio of -10.94 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.
Wall Street Analyst Weigh In
A number of research firms recently commented on EOLS. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Finally, BTIG Research initiated coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $23.75.
View Our Latest Research Report on EOLS
Institutional Trading of Evolus
Hedge funds have recently bought and sold shares of the stock. AlphaQuest LLC purchased a new position in shares of Evolus during the 1st quarter valued at about $39,000. State of Wyoming raised its stake in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after acquiring an additional 3,409 shares during the period. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus during the fourth quarter valued at approximately $106,000. Finally, Rafferty Asset Management LLC bought a new position in shares of Evolus in the fourth quarter worth approximately $115,000. Institutional investors own 90.69% of the company's stock.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
